WJWei Jiang

Wei Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Jiang has a total of 206 co-authors. Here are the top co-authors by number of shared publications:

  • Jing Li

    Department of Gastroenterology Tongji Hospital Tongji University Shanghai China

    13 shared publications
  • Yun Liu

    Department of Rheumatology Zhongshan Hospital Fudan University Shanghai China

    13 shared publications
  • Yue Shen

    Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

    11 shared publications
  • Ji-Yao Wang

    Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Xuhui District, Shanghai, People's Republic of China

    10 shared publications
  • Si-Qi Wang

    Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China

    9 shared publications
  • Lei Li

    Department of Gastroenterology and Hepatology Beijing Youan Hospital Capital Medical University Beijing China

    8 shared publications

Latest Publications

  • Open Access

    Interferon-λ receptor positive monocytes/macrophages orchestrate a pro-fibrotic immune environment in hepatitis B virus-related liver fibrosis

    by Siqi Wang, Shiqin Li, Jun Zhang, Zicheng Liu, Yucheng Zhu, Lisha Cheng, Fangyuan Chen, Yue Shen, Jian Wu, Wei Jiang

    Interferon-λ receptor (IFNLR), a heterodimer composed of IFNLR1 and IL-10Rβ, mediates IFN-λ-driven fibrotic effects. This study investigated the involvement of IFNLR1+ monocytes/macrophages in orchestrating pro-fibrotic immune microenvironment. Flow cytometric analysis of peripheral blood showed that IFNLR1+ monocytes were elevated in patients with chronic hepatitis B virus (HBV) infection (CHI) and patients with HBV-related liver cirrhosis (LC), compared with healthy controls (HC). These cells also displayed a CCR2hiCCR5hiCX3CR1hiCD86hiHLA-DRhiCD163hiMERTKhi phenotype with an IL-10hiTNF-αhi cytokine profile. Hepatic fibrosis was induced in wild-type and Ifnlr1-knockout (Ifnlr1−/−) mice using carbon tetrachloride and recombinant adeno-associated virus 8-1.3HBV. Ifnlr1 deficiency down-regulated CCR2 and CCR5 expression on monocytes/macrophages, attenuated collagen deposition, but enhanced HBV–DNA replication. In vitro, bone marrow-derived macrophages (BMDMs) were co-cultured with hepatic stellate cells (HSCs) or naive CD4+ T cells to assess the functional impact of IFNLR1+ macrophages. Concurrently, the involvement of lipid metabolism in IFN-λ/IFNLR1-mediated macrophage regulation was examined using liver X receptor (LXR) agonists/antagonists. Ifnlr1−/− BMDMs exhibited a diminished capacity to activate HSCs and drive regulatory T cells differentiation. Mechanistically, IFN-λ–IFNLR1 signaling suppressed LXR-dependent lipid metabolism, thereby promoting tumor necrosis factor (TNF)-α and IL-1β production, and LXR pathway inhibition favored M1-macrophage polarization. Collectively, IFNLR1 identifies a pro-fibrotic and immunoregulatory monocyte/macrophage subset. Targeting IFNLR1–LXR axis may represent promising anti-fibrotic strategies for HBV-related liver fibrosis.

  • Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial

    by Yu‐Cheng Zhu, Keng Li, Anjiang Sun, Sihui Lin, Jun Zhang, Shanshan Meng, Xin Xia, Hong Gao, Juan Lin, Wei Jiang

    Background: Resistance to antibiotics has resulted in the effectiveness of conventional eradication therapies for Helicobacter pylori being reduced, creating a need for regimens that are effective, safe, and simple. In this study, we evaluated the eradication efficacy, adverse events, and medication adherence of four different tegoprazan‐based regimens administered as first‐line therapy for H. pylori infection. We also explored the clinical value of adding bismuth to a triple therapy regimen. Methods: In this prospective, randomized controlled trial, 640 treatment‐naive patients with confirmed H. pylori infection were randomly assigned to one of the four groups undergoing 14‐day treatment regimens of tegoprazan–amoxicillin (TA), tegoprazan–tetracycline (TT), tegoprazan–amoxicillin–tetracycline (TAT), or tegoprazan–amoxicillin–tetracycline–bismuth (TATB), with 160 patients in each group. The outcomes were the eradication rate, incidence of adverse events, and medication adherence. Results: In the intention‐to‐treat analysis, the H. pylori eradication rates in the TA, TT, TAT, and TATB groups were 80.0% (95% confidence interval [CI]: 73.0–85.9), 61.9% (95% CI: 53.9–69.4), 93.1% (95% CI: 88.0–96.5), and 89.4% (95% CI: 83.5–93.7), respectively. Compared with the TATB regimen, the TAT regimen was non‐inferior (95% CI, −3.9% to 11.5%; non‐inferiority p < 0.001), whereas demonstrating non‐inferiority in the TA and TT regimens failed. Adverse events were less frequent in the TA (10.6%), TT (17.5%), and TAT (20.0%) groups than in the TATB group (36.9%; all p < 0.001). Medication adherence was high across groups, with no significant between‐group differences observed. Conclusions: High eradication efficacy was demonstrated for the TAT regimen; this regimen was non‐inferior to the TATB regimen, and it was associated with fewer adverse events. These findings suggest that it may be an effective first‐line treatment option for H. pylori infection. Trial Registration: ClinicalTrials.gov identifier: NCT06977841

  • Open Access

    Proliferation, migration, and differentiation of circulating ILC precursors in HBV infection-associated fibrosis

    by Qin Zhu, Fang-Yuan Chen, Shi-Qin Li, Cheng-Zhao Weng, Si-Qi Wang, Lin-Lin Zheng, Yong-Yu Yang, Li Xie, Jian Wu, Wei Jiang

    Background: Increased studies indicate that innate lymphoid cells (ILCs) are involved in inflammatory and immune responses in chronic liver injury. However, recruitment and maturation of their subsets during hepatic fibrosis post-HBV infection are unknown. The present study aims to explore the potential impact of ILC precursors (ILCPs) on the modulation of HBV infection-associated fibrosis. Methods: Peripheral blood mononuclear cells (PBMCs) from healthy controls (HCs), chronic hepatitis B infected (CHB), and cirrhotic patients and lymphoid and splenic mononuclear cells from HBV-transgenic mice were isolated to determine the richness of ILC precursors (ILCPs) and ILC subsets by flow cytometry. Results: The richness of ILCPs and ILC3 subsets was significantly increased in PBMCs of patients with chronic hepatitis B infection and in lymph nodes and spleens of HBV-transgenic mice with carbon tetrachloride treatment. Importantly, among these ILCPs, the percentage of CD62L and CXCR6-expressing ILCPs were proportionally enriched. IL-23 may contribute to CD62L + and CXCR6 + ILCP recruitment and differentiation into ILC3 subsets; whereas a Notch signaling inhibitor DAPT exerted inhibitory effects on them. Conclusion: The microenvironment of HBV infection-associated fibrosis enhances the proliferation, migration, and differentiation of peripheral ILCPs and IIL-23, and Notch signaling pathways may play significant roles in these processes.

  • Open Access

    Global burden of metabolic dysfunction-associated steatotic liver disease from 1990 to 2021 and the prediction for the next 10 years

    by Zhuang Lin, Ruixin Zhang, Shuhao Ren, Tingjuan He, Hongfei Mi, Wei Jiang, Chenghao Su


  • Open Access

    Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis

    by Yameng Sun, Shuyan Chen, Xiaoqian Xu, Hongxin Piao, Guofeng Chen, Wei Jiang, Yongpeng Chen, Mingyi Xu, Huiguo Ding, Wen Xie, et al.

    Background and Aims: Evidence comparing longitudinal liver stiffness measurements (LSMs) dynamics to on-treatment LSM for predicting clinical outcomes in patients receiving etiology therapy is limited. This study aimed to assess the prognostic value of on-treatment LSM in patients with chronic hepatitis B (CHB) receiving antiviral therapy. Approach and Results: This prospective cohort included patients with CHB and significant fibrosis or cirrhosis. Liver-related events (LREs) were defined as hepatic decompensation, liver transplantation, or liver-related death. The association between LREs and baseline, on-treatment, and dynamic changes in LSM was analyzed. A total of 1116 patients with CHB, including 875 (78.4%) diagnosed with cirrhosis, were followed for a median of 7.5 (2.5–9.5) years. On-treatment LSM was the most reliable predictor of 3-year and 5-year outcomes (AUROC: 0.72–0.78) after 1–3 years of antiviral therapy, outperforming baseline LSM (AUROC: 0.59–0.65) and LSM changes (AUROC: 0.42–0.65). Patients with LSM <10 kPa at 1, 2, or 3 years of antiviral therapy have a much lower risk of LREs, with a 5-year cumulative incidence of 2.2%, 2.6%, and 2.7%, respectively. This finding held true in the cirrhosis subgroup, in the validation cohort, and for predicting decompensations alone. Notably, patients with on-treatment LSM <10 kPa showed better restoration of lobular architecture assessed by liver biopsies. Conclusions: On-treatment LSM measured 1–3 years after antiviral therapy offers superior predictive accuracy for LREs compared with baseline or LSM changes, with LSM <10 kPa indicating a significantly lower risk, likely due to improved lobular architecture.


  • Open Access

    Helicobacter pylori Infection and Eradication in Relation to Gastroesophageal Reflux Disease

    by Hejie Wang, Yaxin Qu, Yuan Lin, Zhiqiang Liu, Jesper Lagergren, Shuai Yuan, Eivind Ness‐Jensen, Wei Jiang, Shao‐Hua Xie

    Background and Aim: The effect of Helicobacter pylori (H. pylori) infection and eradication on the risk of gastroesophageal reflux disease (GERD) is still unclear.Methods: We conducted a systematic review with a comprehensive literature search in the bibliographic databases Embase, Medline, and Cochrane Library through May 2024. Random‐effects meta‐analyses estimated the pooled odds ratios (OR) for the associations of H. pylori infection and eradication with GERD risk in prospective studies. A two‐sample Mendelian randomization analysis based on data from the FinnGen study assessed associations between genetically predicted levels of seven H. pylori antibodies, that is, immunoglobulin G (IgG) and six virulence factors (cytotoxin‐associated gene A [CagA], Outer Membrane Protein [OMP], vacuolating cytotoxin A [VacA], urease A [UreA], catalase and GroEL), and GERD risk.Results: A total of 25 eligible studies were included. Meta‐analysis combining data from three cohort studies and one nested case–control study indicated an inverse association between H. pylori infection and GERD (pooled OR = 0.58; 95% confidence interval [CI], 0.23–1.44). Meta‐analysis of 18 cohort studies and three randomized controlled trials (RCTs) showed an increased risk of GERD after H. pylori eradication (pooled OR = 2.01; 95% CI, 1.44–2.81), and this association was stronger when specifically analyzing reflux esophagitis (pooled OR = 2.27; 95% CI, 1.57–3.29). No associations were found in Mendelian randomization analysis for any of the studied H. pylori antibodies. [Correction added on 7 August 2025, after first online publication: The Abstract section has been updated to correct the number of studies for eligible and cohort under the Results.]Conclusions: The study suggests that H. pylori infection is associated with a decreased risk of GERD and that H. pylori eradication increases the risk.


  • Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in HSCs

    by Li Xie, Hui Chen, Li Zhang, Yong-Yu Yang, Yuan Zhou, Yue Ma, Chang Liu, Yu-Li Wang, Qin Zhu, Ya-Jun Yan, et al.

    Background: The succinate receptor GPR91 is highly expressed in hepatic stellate cells (HSCs), with its expression further elevated during metabolic-dysfunction-associated steatohepatitis (MASH)-induced fibrotic progression. However, convincing in vivo data on whether blocking GPR91 signaling leads to fibrotic regression in MASH is lacking. Methods: MASH models were induced by choline-deficient amino acid-defined diet feeding along with lipopolysaccharide injection (CDAA-LPS) plus intraperitoneal injection of succinate or by high-fat and high-calorie diet plus high fructose and glucose in drinking water (HFCD-HF/G) in wild-type (WT) mice and HSC-specific GPR91 knockout (HSC-GPR91-KO) mice. Results: Administration of succinate significantly exacerbated fibrosis in CDAA-fed WT mice, as evidenced by increased collagen deposition and hydroxyproline levels along with an increased GPR91 expression in activated HSCs. Both WT and HSC-GPR91-KO mice exhibited substantial elevation in hepatic succinate levels upon HFCD-HF/G diet feeding. However, in comparison to HFCD+HF/G-fed WT mice, hepatic fibrosis was markedly ameliorated in HSC-GPR91-KO mice, as evidenced by diminished hepatic hydroxyproline content with downregulated fibrogenic markers. Succinate stimulation led to an increase in α-SMA, GPR91, phosphorylated ERK1/2, c-jun and Smad3 protein levels and enhanced the molecular interaction between c-jun and Smad3, inhibited forskolin-induced cAMP production in human HSCs, and increased p-NF-κB transcriptional activity, thereby suppressing HSC apoptosis. Conclusions: HSC-specific GPR91 receptor deficiency effectively halted hepatic fibrosis, probably through two distinct signaling pathways: suppressing the succinate-GPR91-Gβγ-ERK/c-jun-smad3 axis that positively regulates HSC activation; and abrogating the GPR91-Gαi-cAMP-NF-κB pathway that hinders their apoptosis. These findings confer GPR91 as a promising target for molecular interventions in blocking MASH-fibrotic progression. Export In the context of hepatic steatosis, dysfunction of the tricarboxylic acid (TCA) cycle, specifically a reduction in succinate dehydrogenase (SDH) activity, leads to the accumulation and release of succinate into the extracellular space. Excessive succinate acts as a ligand for the G protein-coupled receptor 91 (GPR91) on hepatic stellate cells (HSCs). GPR91 activation triggers a series of intracellular signaling events through the Gαi and Gβγ subunits. Interaction with the Gαi subunit reduces cAMP levels, diminishes protein kinase A (PKA) activity, and leads to decreased phosphorylation of NF-κB, thereby inhibiting HSC apoptosis. Simultaneously, GPR91 activation via the Gβγ subunits promotes the phosphorylation of ERK1/2 and c-jun, facilitating the interaction between c-jun and Smad3, which subsequently activates HSCs through Smad3-mediated pathways. The sustained activation of HSCs results in excessive extracellular matrix (ECM) synthesis, contributing to hepatic fibrogenesis. Deletion of GPR91 in HSCs or the use of GPR91 antagonists effectively suppresses the onset and progression of MASH-induced fibrosis.


  • Open Access

    Clinical Impact of High-dose Esomeprazole-amoxicillin Dual Therapy as Rescue Treatment for Helicobacter pylori Infection

    by Chao Mm Wang, He-Jie Mm Wang, Keng Mm Li, Yin Mm Wang, Yuan-Yuan Lin, Cheng-Zhao Mm Weng, Jie Chen, Shao-Hua Xie, Wei Jiang, Yu-Cheng Zhu

    Objective: This study aimed to compare the effectiveness and safety of high-dose dual therapy (HDDT) using esomeprazole and amoxicillin to furazolidone-based quadruple therapy (FBQT) in treating nonresponsive patients with Helicobacter pylori (H. pylori) infection. Materials and Methods: A total of 209 patients with H. pylori infection, who had previously received ineffective treatment and visited an outpatient clinic, were randomly assigned to either the HDDT or FBQT groups. All patients underwent a 14-day treatment regimen, and the success rates of H. pylori eradication and safety of the treatment regimens were assessed 4 weeks posttreatment. Results: Following the 14-day treatment period, the intention-to-treat (ITT) analysis revealed eradication rates of 93.6% for HDDT and 86.9% for FBQT. In the per-protocol (PP) analysis, eradication rates were 94.5% for HDDT and 88.7% for FBQT. No significant difference in eradication rates was observed between the two groups. HDDT exhibited significantly lower rates of adverse reactions (9.1% in ITT and 9.2% in PP) compared with FBQT (58.6% in ITT and 59.8% in PP). Multivariate analysis identified interval time, alkaline phosphatase, and serum creatinine level as factors influencing the eradication rate. The area under the receiver operating curve of the interval time between the FBQT group and the HDDT group and the success of H. pylori eradication were 0.622 and 0.578, respectively. The optimal salvage treatment intervals were determined as 6 months for FBQT and 1 year for HDDT. Conclusion: HDDT using high-dose esomeprazole and amoxicillin demonstrated efficacy in treating H. pylori infection, with the added benefits of reduced side effects and improved medication compliance compared with FBQT. HDDT can be considered a rescue treatment option when other methods fail, with treatment intervals optimized accordingly.


  • Open Access

    Upper Esophageal Sphincter Abnormalities and Esophageal Motility Recovery After Peroral Endoscopic Myotomy for Achalasia

    by Sihui Lin, Tiancheng Luo, Zhilong Chen, Yucheng Zhu, Shuqiang Weng, Wei Jiang, Hong Gao

    Abnormalities in the upper esophageal sphincter (UES) in patients with achalasia and the impact of peroral endoscopic myotomy (POEM) on the UES and esophageal body remain uncertain. To outline the prevalence and nature of UES abnormalities across different achalasia subtypes, as well as evaluate POEM’s therapeutic efficacy on UES and esophageal body. A retrospective study of patients diagnosed with achalasia between January 2019 and December 2023 was conducted. POEM was performed on all patients, and preoperative and 6-month postoperative high-resolution esophageal manometry (HREM) data were obtained, along with the Eckardt symptom scores. A total of 64 patients (34 females, 30 males) who underwent POEM for achalasia (type I: 18, type II: 38, type III: 8) during the study period were included. Among the 64 patients, 42 (65.6%) exhibited abnormalities in the UES, as observed on HREM. The majority of those exhibiting abnormalities demonstrated impaired relaxation of the UES (46.9%), followed by a combination of hypertensive basal UES pressure (UESP) and impaired UES relaxation (12.5%). The dysphagia score and Eckardt score before POEM were significantly greater in the UES abnormality group than in the normal UES group (2.3 ± 0.7 vs. 1.9 ± 0.7, p = 0.040 and 6.2 ± 1.8 vs. 5.0 ± 1.6, p = 0.008, respectively). UESP and UES relaxation pressure (UESRP) decreased significantly following POEM across all types of achalasia (p < 0.05). All type I patients continued to exhibit no contractility after undergoing POEM. Pan-esophageal pressurization and spastic contractions were absent in patients with type II and type III achalasia following POEM. The high prevalence of UES abnormalities among patients with achalasia may serve as a compensatory mechanism. Patients with type II and III showed partial recovery of peristalsis following POEM.


  • Open Access

    Targeting BRD4 mitigates hepatocellular lipotoxicity by suppressing the NLRP3 inflammasome activation and GSDMD-mediated hepatocyte pyroptosis

    by Fangyuan Chen, Shuyu Li, Min Liu, Cheng Qian, Zhiyin Shang, Xu Song, Wei Jiang, Chuantao Tu

    Nod-like receptor family pyrin-containing protein 3 (NLRP3) inflammasome plays a pathologic role in metabolic dysfunction-associated steatohepatitis (MASH), but the molecular mechanism regulating the NLRP3 inflammasome activation in hepatocellular lipotoxicity remains largely unknown. Bromodomain-containing protein 4 (BRD4) has emerged as a key epigenetic reader of acetylated lysine residues in enhancer regions that control the transcription of key genes. The aim of this study is to investigate if and how BRD4 regulated the NLRP3 inflammasome activation and pyroptosis in MASH. Using the AML12 and primary mouse hepatocytes stimulated by palmitic acid (PA) as an in vitro model of hepatocellular lipotoxicity, we found that targeting BRD4 by genetic knockdown or a selective BRD4 inhibitor MS417 protected against hepatosteatosis; and this protective effect was attributed to inhibiting the activation of NLRP3 inflammasome and reducing the expression of Caspase-1, gasdermin D (GSDMD), interleukin (IL)-1β and IL-6. Moreover, BRD4 inhibition limited the voltage-dependent anion channel-1 (VDAC1) expression and oligomerization in PA-treated AML12 hepatocytes, thereby suppressing the NLRP3 inflammasome activation. Additionally, the expression of BRD4 enhanced in MASH livers of humans. Mechanistically, BRD4 was upregulated during hepatocellular lipotoxicity that in turn modulated the active epigenetic mark H3K27ac at the promoter regions of the Vdac and Gsdmd genes, thereby enhancing the expression of VDAC and GSDMD. Altogether, our data provide novel insights into epigenetic mechanisms underlying BRD4 activating the NLRP3 inflammasome and promoting GSDMD-mediated pyroptosis in hepatocellular lipotoxicity. Thus, BRD4 might serve as a novel therapeutic target for the treatment of MASH. Graphic abstract